GAMES (Glyburide Advantage in Malignant Edema and Stroke) RP Trial: Intermediate Endpoint Analysis as Proof-Of-Concept (S7.006)

Conclusions: RP-1127 reduced neuroimaging markers of brain edema and total MMP-9 level.Disclosure: Dr. Kimberly has received research support from Remedy Pharmaceuticals, Inc. Dr. Elm has received research support from Remedy. Dr. Hinson has nothing to disclose. Dr. Molyneaux has nothing to disclose. Dr. Beslow has nothing to disclose. Dr. Sze has received research support from Remedy. Dr. Ostwaldt has received research support from Remedy. Dr. Del Zoppo has received research support from Remedy. Dr. Simard has received royalty payments from Remedy. Dr. Sheth has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Kimberly, W. T., Elm, J., Hinson, H., Molyneaux, B., Beslow, L., Sze, G., Ostwaldt, A.-C., Del Zoppo, G., Simard, M., Sheth, K. Tags: Stroke Clinical Trials Source Type: research